Our Mission: “To accelerate curative therapies for multiple myeloma and related disease entities through innovative translational research and outstanding patient care.” – Myeloma Institute for Research and Therapy
Myeloma Institute doctors presented research findings at the annual meeting of the American Society of Hematology (ASH), December 10-13. You can view ASH Abstracts at http://ash.confex.com/ash/2011/webprogram/start.html (search by “Barlogie”).
Onyx Therapeutics, Inc. has awarded $1 million over a two year period to Dr. Saad Usmani, Director of Developmental Therapeutics at the Myeloma Institute, for collaborative research studies, with specific focus on the Institute’s Total Therapy 5B and Total Therapy 7 protocols.
The Myeloma Institute announces the recent departure of John D. Shaughnessy, Jr., Ph.D., Director of Basic Research. After nearly 14 years with the Myeloma Institute, Dr. Shaughnessy has assumed a full-time position in the private sector with Signal Genetics to pursue development of targeted medications and treatments for multiple myeloma.
Jodi, I will say, that I hear good things from patients about all the doctors there. And we have had to change twice now. Each time I start to hyperventilate at having to meet a new doctor and each time it is one of the most pleasant transitions I have ever experienced.
Our hero….Dr. Usmani…we are blessed to have him
in our corner!